Daré Bioscience has formed a strategic collaboration with digital health platform Rosy Wellness to support the marketing campaign for its DARE to PLAY Sildenafil Cream, targeting fourth-quarter 2025 availability in the United States.
The partnership combines Daré’s clinical expertise in women’s health with Rosy’s digital reach to a community of over 250,000 women. Rosy Wellness operates an app focused on evidence-based women’s sexual health and wellness support.
DARE to PLAY Sildenafil Cream contains sildenafil citrate, the same active ingredient found in Viagra, formulated as a topical treatment to increase blood flow to genital tissues as part of the female sexual arousal response. The company plans to make the product available by prescription as a compounded drug under Section 503B of the Federal Food, Drug, and Cosmetic Act.
“Female sexual health remains significantly underserved, and we believe our DARE to PLAY Sildenafil Cream represents a meaningful advancement,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Partnering with Rosy allows us to connect with women in a trusted, authentic space that encourages open discussion and education about sexual wellness.”
The collaboration addresses a substantial market need. Among women in Rosy’s community who completed the Female Sexual Function Index screener questionnaire, 65% reported concerns with arousal.
Rosy Wellness, founded by board-certified OB-GYN Lyndsey Harper, provides cognitive behavioral therapy-based exercises, expert-led health coaching, and community support for women’s sexual health issues. The platform will support the product launch through educational campaigns and a companion care platform designed to support users throughout their treatment journey.
“At Rosy, we’re committed to closing gaps in women’s healthcare with evidence-based, accessible solutions,” said Lyndsey Harper, MD, Founder and CEO of Rosy. “This partnership with Daré accelerates our efforts to bring much needed attention and resources to sexual wellness, a historically stigmatized area.”
Daré expects to begin recording revenue from the product in the fourth quarter of 2025, coinciding with its targeted availability timeline. The San Diego-based biopharmaceutical company focuses on developing women’s health solutions, often leveraging existing clinical proof of concept or safety data for active ingredients to optimize market access.
The company’s portfolio includes Ovaprene, a hormone-free monthly intravaginal contraceptive under license agreement with Bayer, and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. Daré’s first FDA-approved product, XACIATO (clindamycin phosphate) vaginal gel 2% for bacterial vaginosis treatment, operates under a global license agreement with Organon.
